Validation of a prognostic model to predict survival after non-small-cell lung cancer surgery

European Journal of Cardio-thoracic Surgery

Volumn 38, Issue 5, 2010, Pages 615-619

  van der Pijl, Leonardus L R ^a   Birim, Özcan ^a   van Gameren, Menno ^a   Kappetein, Arie Pieter ^a   Maat, Alex P W M ^a   Steyerberg, Ewout W ^a   Bogers, Ad J J C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Model; NSCLC; Surgery; Survival; Validation

Indexed keywords

ADULT; AGED; ARTICLE; CALIBRATION; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOMA; LUNG LARGE CELL CARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SMOKING HABIT; SURVIVAL TIME; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; TREATMENT OUTCOME;

EID: 77957919553     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.03.028     Document Type: Article

References (20)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics 2008. CA Cancer J Clin 2008, 58:71-96.
2. Birim O., Kappetein A.P., Waleboer M., Puvimanasinghe J.P.A., Eijkemans M.J.C., Steyerberg E.W., Versteegh M.I.M., Bogers A.J.C.C. Long-term survival after non-small cell lung cancer surgery: Development and validation of a prognostic model with a preoperative and postoperative mode. J Thorac Cardiovasc Surg 2006, 132:491-498.
3. WHO. The World Health Organization. Histological typing of lung tumours. Am J Clin Pathol 1982;77:123-36.
4. Mountain C.F. Revision in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717.
5. Altman D.G., Royston P. What do we mean by validating a prognostic model?. Stat Med 2000, 19(February (4)):453-473.
6. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models. Stat Med 1996, 15:361-387.
7. Hosmer D.W., Lemeshow S. Applied logistic regression 2000, John Wiley & Sons, New York. 2nd ed. D.W. Hosmer, S. Lemeshow (Eds.).
8. Bleeker S.E., Moll H.A., Steyerberg E.W., Donders A.R., Derksen-Lubsen G., Grobbee D.E., Moons K.G. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 2003, 56:826-832.
9. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., Yamamoto S., Nokihara H., Yamamoto N., Sekine I., Kunitoh H., Shibata T., Sakiyama T., Yoshida T., Tamura T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:6829-6837.
10. Shepherd F.A., Tsao M.S. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006, 24:1219-1220.
11. Brundage M.D., Davies D., Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002, 122:1037-1057.
12. Shepherd F.A., Rosell R. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2007, 2(Suppl. 2):S68-S76.
13. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., Lin L., Chen G., Gharib T.G., Thomas D.G., Lizyness M.L., Kuijck R., Hayasaka S., Taylor J.M., Iannettoni M.D., Orriger M.B., Hanash S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:816-824.
14. Bhattacharjee A., Richards W.G., Staunton J., Mont S., Vasa P., Ladd C., Beheshti J., Bueno R., Gillett M., Loda M., Weber G., Mark E.J., Landers E.S., Wong W., Johnson B.E., Golub T.R., Sugerbaker D.J., Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001, 98:13790-13795.
15. Potti A., Mukherjee S., Petersen R., Dressman H.K., Bild A., Koontz J., Kratzke R., Watson M.A., Kelley M., Ginsburg G.S., West M., Harpole D.H., Nevins J.R. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006, 355:570-580.
16. Raponi M., Zhang Y., Yu J., Chen G., Lee G., Taylor J.M.G., MacDonald J., Thomas D., Moskaluk C., Wang Y., Beer D.G. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006, 66:7466-7472.
17. Wigle D.A., Jurisica I., Radulovich N., Pintilie M., Rossant J., Liu N., Lu C., Woodgett J., Seiden I., Johnston M., Keshavjee S., Darling G., Winton T., Breitkreutz B.J., Jorgenson M., Tyers M., Shepherd F.A., Tsao M.S. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002, 62:3005-3008.
18. Chen H.Y., Yu S.L., Chen C.H., Chang G.C., Chen C.Y., Yuan A., Cheng C.L., Wang C.H., Terng H.J., Kao S.F., Chan W.K., Li H.N., Liu C.C., Singh S., Chen W.J., Chen J.J.W., Yang P.C. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356:11-20.
19. Lau S.K., Boutros P.C., Pintilie M., Blackhall F.H., Zhu C.Q., Strumpf D., Johnston M.R., Darling G., Keshavjee S., Waddel T.K., Liu N., Lau D., Penn L.Z., Shepherd F.A., Jurisica I., Der S.D., Tsao M.S. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007, 25:5562-5569.
20. Rami-Porta R., Crowley J.J., Goldstraw P. The revised TNM Staging System for Lung Cancer. Ann Thorac Cardiovasc Surg 2009, 15:4-9.